Liws Opposition jubilant over PM s ouster
NEW DELHI:After a number of back-to-back successful film releases, Kangana Ranaut has rightfully been dubbed the 鈥楺ueen鈥?of Bollywood. But for the talented actor, success doesn鈥檛 come with any kind of pressure. In fact, Ranaut believes that failure doesn鈥檛 reflect one鈥檚 credibility as an artist at all.According to the Tanu Weds Manu star, she doesn鈥檛 pick a project thinking how it will elevate her position in the Indian film industry. 鈥淚 haven鈥?
stanley website
t set any standards that I have to do this work or this is where I have to go. I don鈥檛 put that kind of pres
adidas campus nere
sure on myself,鈥?she said in a recent interview. 鈥淲hat I tell myself is that I will continue on this path. I think I鈥檓 probably the only top female actor who has done B-grade films. I don鈥檛 see that a certain project can ascend you to a certain position. You can be giving flops and still be a valuable artist 鈥?that is the case with me.鈥漈he actor, who is known for her brazen
new balance bleu
honesty, feels that, 鈥淚t really doesn鈥檛 matter what films you do. W Karus Therapeutics (
nike air force1
鈥楰arus鈥? has announced that the first patients have been dosed in a Phase I study for its lead candidate, KA2237. This is the Company鈥檚 first product to enter clinical trials. KA2237 is a dual-selective inhibitor of two PI3K isoforms, p110尾 and p110未. Inhibiting these two isoforms combines a
asics schuhe
n immunotherapeutic response and a direct effect on tumor growth, through selective, targeting of the PI3K pathway. Karus believes that KA2237 has broad therapeutic applicability in the treatment of hematological and solid tumors, as a single agent and in combination with other drugs.This study forms part of the pre-clinical and clinical collaboration between Karus and the University of Texas MD Anderson Cancer Center, the world鈥檚 leading cancer research and care center. The first part of the trial has been designed to assess the safety of KA2237 alone
dunk panda
in relapsed, treatment-resistant B cell lymphoma patients. An expansion cohort study will follow and is scheduled to start in 201